PEPID Connect Help
View Tutorial
Contact PEPID Support
Suggest an edit
Current tool:
Current monograph:
Hello, PEPID User
PEPID
Subsections
Intracerebral Hemorrhage

Neurology

Intracerebral Hemorrhage

Background

  1. Definition
    • Hemorrhagic stroke characterized by bleeding into the parenchyma of the brain
    • Aka intracranial hemorrhage
  2. General Information
    • Ottawa SAH Rule being developed
      • Not validated, requires further investigation
    • Blood pressure reduction guidelines
      Not
      • standardized
      • Controversy over aggressiveness of BP management
      • Evidence is incomplete
    • ICH represents 8-11% of acute strokes
      • High morbidity/mortality
      • Requires frequent re-evaluation
        • Clinical presentation can evolve quickly
    • Mainstays of Management
      • Early detection
        • CT (non-contrast) initial study of choice
      • Minimizing secondary complications and ongoing injury
        • BP management
        • Reversal of anticoagulation
      • Disposition for evaluation of early surgical intervention
  3. Epidemiology
    • Incidence/Prevalence
      • Incidence of stroke (both ischemic and hemorrhagic in 2010)
        • 33 million globally
          • Hemorrhagic strokes account for nearly a 1/3 of cases and 1/2 of deaths
      • Twice as common as SAH
      • Global incidence: 20 cases/100,000 people/year
      • Men > women
      • Asian and young-middle age African American > Caucasian

Pathophysiology

  1. Pathogenesis
    • Bleeding into brain parenchyma
    • Degenerative changes in penetrating arteries/arterioles lead to microaneurysm's, subsequent rupture
      • Most commonly penetrating vessels of the MCA (2/3 affecting basal ganglia)
      • Hematoma enlarges, causing local tissue injury, increased ICP
      • Low blood flow state alters electrical conduction of neurons but initially leaves cell membranes intact, salvageable
      • Once critical decrease in blood flow occurs, cell membrane destruction and irreversible damage occurs
    • ICH is complicated by red cell lysis and edema leading to increased blood-brain barrier permeability which can lead to secondary injury
  2. Etiology/Risk Factors
    • Nontraumatic intracerebral hemorrhage can be divided into primary and secondary
      • Primary bleeds (85%)
        • Related to chronic hypertension
        • Amyloid angiopathy
      • Secondary bleeds
        • Bleeding diathesis
        • Vascular malformations
          • AV malformations
          • Cavernous angiomas
          • Cerebral aneurysms
          • Aorto-venous fistulae
        • Neoplasms
        • Hemorrhagic conversion of an ischemic stroke
        • Drug abuse
    • Combine with other injuries to cause mass effect/herniation
      • Contusions
      • Other hematomas
      • Edema around lesions
    • Clinical effects depend on
      • Size of hematoma
      • Location
      • If bleeding stops or is continuous
    • Elderly
    • Male sex
    • Predilection is seen in African and Asian populations
      • Japanese have high incidence of ICH

Diagnostics

  1. History/Symptoms
    • Acute onset, unheralded
    • Deficits develop over mins-hrs
    • Occur during waking hrs
    • Headache (50%)
      • Acute onset
      • "Worst headache of life"
      • Thunderclap, pop, snap, or gunshot sound in head
      • Exertional headache
    • Fainting or passing out
    • Seizure at onset
    • Vomiting
    • Declining mental status
    • Cerebral hemorrhage clinically difficult to distinguish from cerebral ischemia
    • PNH
      • Hypertension
      • Premorbid neurologic status
      • Premorbid cognitive status
    • Social Hx
      • Alcohol abuse
      • Drug abuse (cocaine)
    • Family Hx
      • Aneurysms
      • AV malformations
  2. Physical Examination/Signs
    • Clinically difficult to differentiate from ischemic stroke or SAH
    • ABCs
    • Neuro exam (focused)
      • Note:
        • Neuro exam may be normal initially (especially if SAH)
      • Level of consciousness (LOC)
      • Speech
      • Cranial nerve (CN) function
      • Motor function: tone, strength, pronator drift
      • Sensory function: light touch, pain
      • Cerebellar function: finger -to -nose, heel -to -shin
      • DTRs
      • Babinski's sign
    • Look for signs of head trauma
    • Fever
      • Infectious vs central
      • Central: associated with large and intraventricular bleeds
    • A baseline severity score should be performed as part of the initial evaluation of patients with ICH:
    • Findings (based on type of lesion):
      • Putamen hemorrhage
        • Contralateral hemiplegia and hemisensory loss, eye deviation toward hemorrhage, visual field deficits
        • Possible aphasia or neglect
      • Cerebellar hemorrhage
        • Neck stiffness
        • HA, vomiting, ataxia (View Video)
        • Strength/sensation may be normal except for ipsilateral facial weakness
        • Cannot look toward side of bleed
        • Possible rapid clinical deterioration
      • Thalamic hemorrhage
        • Contralateral hemiparesis and hemisensory loss
        • Small, nonreactive pupils with downward gaze
      • Pontine hemorrhage
        • If patient is awake, may experience facial palsy, deafness, dysarthria
        • "Locked-in" state with small pinpoint pupils
        • Usually fatal
    • Poor prognostic factors:
      • Decreased level of consciousness (LOC) on arrival
      • Large intracranial hemorrhage
      • Intraventricular hemorrhage
  3. Diagnostic Testing
    • Laboratory Evaluation
    • Other studies
      • NIH Stroke Scale (Open Calc)
      • HAT Score for Predicting Post-tPA Hemorrhage (Open Calc)
      • Intracerebral Hemorrhage Score (Open Calc)
      • FUNC Score (Open Calc)
      • Secondary Intracerebral Hemorrhage (sICH) Score (Open Calc)
      • PHASES Score (Open Calc)
      • ECG
        • Rule out: ACS, Afib, other dysrhythmias (often present)
      • Lumbar puncture
        • Not routinely recommended
        • Check for xanthochromia (with concern for ICH and negative CT)
      • EEG monitoring
      • Additional lab tests based on clinical judgment and considered differential
  4. Diagnostic Imaging
    • Rapid neuroimaging with CT or MRI is recommended to distinguish ischemic stroke from ICH
      • CTA and contrast-enhanced CT may be considered: risk for hematoma expansion (COR IIb; LOE B)
      • CTA, CT venography, contrast-enhanced CT, contrast-enhanced MRI, MRA, MR venography, and catheter angiography
        • Evaluate for underlying structural lesions (e.g., vascular malformations, tumors) when there is clinical or radiological suspicion (COR IIa; LOE B)
    • CT scan (non-contrast)
      • Initial diagnostic test of choice
      • Most sensitive within 6 hrs (View image)
      • Evaluate for evidence of hemorrhage
      • Detects bleeds > 1 cm diameter
      • High risk of hydrocephalus if blood present in the ventricles
    • MRI
      • Limited usefulness in ED setting
      • Evaluate for structural lesions, tumors
      • Questionable accuracy in acute hemorrhage
        • May be as accurate as CT for acute
        • More accurate for chronic and microbleeds
      • MRI Axial (View image)
      • MRI Sagittal (View image)
    • CT angiography (CTA)
      • High -quality imaging of larger arteries
      • DSA Frontal (View image)
      • Exclude aneurysm
      • Consider for:
        • Cause of bleeding not established
        • Stable patients
    • CT venography (CTV)
      • Consider if CVST suspected (multifocal hemorrhages in nonarterial distributions)
    • CXR
      • Not routinely recommended
      • Consider if other etiology suspected

Differential Diagnosis

  1. Subarachnoid hemorrhage
  2. Epidural hemorrhage
  3. Subdural hemorrhage
  4. Ischemic stroke
  5. Tumor +/- bleed
  6. Meningitis
  7. Cervical artery dissection
  8. Idiopathic intracranial HTN
  9. Amyloid angiopathy
  10. Bleeding coagulopathy
  11. Hypoglycemic episode
  12. Drug overdose
  13. Seizure
  14. Metabolic disturbance
  15. Shock

Treatment

  1. Acute Treatment
    • ABCs, O2
      • Ongoing airway monitoring
    • Keep patient NPO
      • Until speech evaluated
    • 2 large-bore IV lines (if available)
      • Maintenance fluids
      • Isotonic crystalloids for dehydration
    • Stop anticoagulant
    • Coagulopathy
      • Identify and reverse underlying coagulopathy if possible
      • Newer anticoagulants may not have a reversal agent
        • Consult hematology
    • Serial neuro exams
      • Monitor progression of symptoms
    • Cardiac monitor
      • Watch for dysrhythmias (common)
    • Monitor & control:
      • Blood pressure
      • Glucose
      • Intracranial pressure (ICP)
      • Body temperature
    • Intubation
      • Patient may rapidly deteriorate
      • Be ready to intubate early
      • Perform neuro exam before intubating
    • Decrease brain edema if present
    • Consult neurosurgery
      • Surgical assessment and procedural intervention
  2. Medical/Pharmaceutical
    • BP control
      • For ICH patients presenting with SBP between 150-220 mmHg and without contraindication to acute BP treatment
        • Acute lowering of SBP to 140 mmHg is safe (COR I; LOE A)
          • Can be effective for improving functional outcome (COR IIa; LOE B)
      • For ICH patients presenting with SBP > 220 mmHg
        • Consider aggressive reduction of BP with a continuous IV infusion and frequent BP monitoring (COR IIb; LOE C)
      • AVOID rapid swings in blood pressure
        • Do not reduce MAP by > 20%
        • Reduce BP slowly over 3-6 hrs
        • Reducing BP too much or too quickly may cause hypotensive events (syncope)
      • Beta-blockers
        • Labetalol: 5-20 mg bolus every 10-15 min; infusion 2 mg/min (max 300 mg/day)
        • Esmolol: 250 mcg/kg bolus loading; infusion 25-300 mcg/kg/min
      • CCBs
      • ACE-I
      • Vasodilators
        • Hydralazine
          • Bolus 5-20 mg every 30 min
          • Infusion 1.5-5 mcg/kg/min (if pregnant)
        • Nitroglycerin: Infusion 20-400 mcg/min (signs of heart failure of ACS)
        • Nitroprusside
          • Infusion 0.1-10 mcg/kg/min
          • If refractory HTN, high risk of side effects including hypotension
          • May increase ICP
    • Analgesia and sedation
      • For unstable patients requiring intubation and ventilation (see RSI)
        • Always perform neuro exam before intubating
        • Titrate to minimize pain and minimize increases in ICP
      • Pre-treatment medications
        • Lidocaine
          • 1.5 mg/kg IV to max of 100 mg 3 min prior to RSI
          • Does blunt catecholamine release but unclear the effect on ICP (no good studies)
          • Con: No evidence that pre-treatment lowers mortality
          • Pro: Little harm from one dose
        • Fentanyl
          • 1 mcg/kg IV 3 min prior to RSI
          • Also blunt catecholamines leading to decrease HR and BP but unclear if lowers ICP
          • Con: No evidence that pretreatment lowers mortality
          • Pro: Little harm from one dose, and likely the analgesic of choice post RSI and ETT placement
      • RSI Medications: no specific recommendations
    • Post RSI and ETT placement
      • Analgesics: fentanyl, alfentanil, morphine
        • These medications/sedation may have blood pressure lowering effects
      • Sedatives: Propofol, Thiopental, Versed
      • Continuous neuromuscular paralysis not recommended prophylactically (increases risk of pneumonia and masks seizure activity)
      • If refractory (ICP elevation not responding to medical management): reducing muscle activity can lower ICP
      • Ventilation
        • 100% O2 at 10-12 breaths/min
        • Tidal volume 10 cc/kg
        • Avoid hyperventilation
          • Reduces ICP only short-term
          • Reserved for cases with impending edema
    • Reverse anticoagulation
      • Revised guidelines
        • If ICH with INR elevated because of VKA: Withhold VKA, receive therapy to replace vitamin K–dependent factors and correct the INR, receive IV vitamin K
        • PCCs may have fewer complications and correct the INR more rapidly than FFP and might be considered over FFP
        • rFVIIa is not recommended for VKA reversal in ICH
          • rFVIIa does not replace all clotting factors, and although the INR may be lowered, clotting may not be restored in vivo
        • Activated charcoal might be used if the most recent dose of dabigatran, apixaban, or rivaroxaban was taken < 2 hrs earlier
          • Hemodialysis might be considered for dabigatran
        • Protamine sulfate may be considered to reverse heparin in acute ICH
      • Stop Anticoagulant
      • Warfarin reversal:
      • Heparin reversal:
      • If thrombocytopenia (< 100,000)
        • Consider platelet transfusion
    • Seizure
      • Prophylaxis
        • Benefit of routine prophylaxis not clear; not recommended
        • Indicated for patients who have had a seizure
        • Phenytoin 20 mg/kg IV
        • Levetiracetam 500-1,500 mg IV
      • Active seizure
      • If seizures persist
      • Continuous EEG monitoring if available should be started
    • Cerebral edema
      • Raise head of bed to 30 degrees
      • Hyperventilate
        • Goal: pCO2 28-32 mm Hg for short periods only
      • Mannitol
        • 1 g/kg IV bolus, then 0.25-0.5 g/kg every 6 hrs
        • Target plasma osmolality of 300-310
      • Hypotonic fluids
        • Contraindicated
        • Mild hypernatremia should be tolerated
      • Hypertonic saline
        • May be used
        • Shown to reduce ICP even in refractory cases
        • No guidelines regarding concentration of administration
      • Glucose control
        • Maintain 140-180 mg/dL range
        • Avoid hypo/hyperglycemia
      • Barbiturate coma
        • For refractory intracranial hypertension
        • Involves significant risk and intensive monitoring, (NOT first line therapy)
    • Corticosteroids should not be administered for treatment of elevated ICP in ICH (COR III; LOE B)
  3. Surgical/Procedural
    • Potential ventriculostomy, craniotomy, evacuation
      • Cerebellar bleed: limited space in this part of the brain; swelling leads to rapid compartment syndrome-like cell death
    • Therapeutic cooling (aka therapeutic hypothermia) may be used
      • Not first line therapy; studies show neuroprotection from cooling and worse outcomes with fever in ICH
        • No evidence yet linking this therapy to benefit in ICH
        • Note: high rate of complications with this therapy and risk for rebound IC hypertension
      • Therapeutic cooling to 32-34°C may be used
      • No benefit of expensive equipment vs ice packs and cold IVF
  4. Further Treatment
    • Optimize cerebral perfusion
      • Treat systemic shock
      • Treat hypoxia
    • Good general medical care
    • Monitor ICP and arterial pressure
      • Keep ICP < 20
      • Keep CPP < 70
    • Repeat head CT as needed
  5. Complications of Treatment
    • Precipitous or large reduction in BP may result in
      • Hypotension
      • Significantly reduced cerebral perfusion pressure
      • Worsening injury
    • Hypoglycemic episode from glucose control
    • Hypotension if barbiturate coma used
    • Rebound ICP elevation risk with rapid cessation of therapeutic cooling or prolonged hyperventilation
    • Standard risk of neuromuscular blockade if used
    • Renal failure precipitation with hyperosmotic hypovolemic state from mannitol use
  6. Prevention
    • DVT prophylaxis with compression stalking
      • Should have intermittent pneumatic compression for prevention of venous thromboembolism beginning the day of hospital admission
      • Graduated compression stockings are not beneficial to reduce DVT or improve outcome
    • Systemic anticoagulation or IVC filter placement is probably indicated in ICH patients with symptomatic DVT or PE
      • The decision between these 2 options should take into account several factors, including
        • Time from hemorrhage onset
        • Hematoma stability
        • Cause of hemorrhage
        • Overall patient condition
    • Aspiration precautions
    • Outpatient: hypertension control and cessation of smoking, heavy alcohol, or cocaine use

Follow-Up

  1. Hospital/ED Admission
    • Admit all hemorrhagic CVA patients, ICU recommended
      • Up to 52% mortality, most deaths within first 48 hrs
    • OR for evacuation PRN increased ICP, edema
  2. Possible Consultations
    • Neurology
    • Neurosurgery
    • Radiology

Prognosis

  1. Morbidity/Mortality
    • Mortality
      • 1 month: 40% (half in first 2 days)
      • 1 year: 54%
      • 5 years: 71%
      • 10 years: 80%
    • Among survivors, only 20% living independently at 6 months
    • LOW if patient is conscious before surgery
    • Up to 45% if patient unconscious
    • HIGH mortality if:
      • Bleed into ventricles
      • Cerebellar hematoma

Prevention

  1. DVT prophylaxis with compression stalking
    • Should have intermittent pneumatic compression for prevention of venous thromboembolism beginning the day of hospital admission
    • Graduated compression stockings are not beneficial to reduce DVT or improve outcome
  2. Systemic anticoagulation or IVC filter placement is probably indicated in ICH patients with symptomatic DVT or PE
    • The decision between these 2 options should take into account several factors, including
      • Time from hemorrhage onset
      • Hematoma stability
      • Cause of hemorrhage
      • Overall patient condition
    • Aspiration precautions
    • Outpatient: hypertension control and cessation of smoking, heavy alcohol, or cocaine use

References

  1. Barnett HJ, Mohr JP, Stein BM (Eds). Stroke pathophysiology, diagnosis, and management. Churchill Livingstone:Philadelphia 1998
  2. Perry JJ, Stiell IG, Sivilotti MA, et al. Clinical Decision Rules to Rule Out Subarachnoid Hemorrhage for Acute Headache. JAMA. 2013;310(12):1248-1255
  3. Perry JJ, Stiell IG, Sivilotti MA, et al. Sensitivityof computed tomography performed within six hours of onset of headache for diagnosis of subarachnoid haemorrhage: prospective cohort study. BMJ. 2011;343:d4277
  4. Edlow JA, Panagos PD, Godwin SA, Thomas TL, Decker WW; American College of Emergency Physicians. Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with acute headache. Ann Emerg Med. 2008;52(4):407-436
  5. Broderick J, Connolly S, et al. Guidelines for the management of spontaneous intra- cerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke 38:2001, 2007
  6. Kidwell CS, Chalela JA, Saver JL, et al. Comparison of MRI and CT for detection of acute intracerebral hemorrhage. JAMA 2004;292:1823
  7. Morgenstern LB, Hemphill JC 3rd, Anderson C, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2010;41:2108
  8. Ohwaki K, Yano E, Nagashima H, et al. Blood pressure management in acute intracerebral hemorrhage: relationship between elevated blood pressure and hematoma enlargement. Stroke 2004;35:1364
  9. Garg RK, Liebling SM, Maas MB, et al. Blood pressure reduction, decreased diffusion on MRI, and outcomes after intracerebral hemorrhage. Stroke 2012;43:67
  10. Anderson CS, Heeley E, Huang Y, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med 2013;368:2355
  11. Anderson CS, Huang Y, Arima H, et al. Effects of early intensive blood pressure-lowering treatment on the growth of hematoma and perihematomal edema in acute intracerebral hemorrhage: the Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT). Stroke 2010;41:307
  12. Broderick JP, Brott TG, Duldner JE, et al. Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality. Stroke 1993;24:987
  13. Zia E, Engström G, Svensson PJ, et al. Three-year survival and stroke recurrence rates in patients with primary intracerebral hemorrhage. Stroke 2009;40:3567
  14. Franke CL, van Swieten JC, Algra A, van Gijn J. Prognostic factors in patients with intracerebral haematoma. J Neurol Neurosurg Psychiatry 1992;55:653
  15. Crocco TJ, Tadros A, Kothari RU. Chapter 99, Stroke. Rosen’s Emergency Medicine 2010. 1333-45
  16. Diringer MN, Zazulia AR. Osmotic therapy: fact and fiction. Neurocrit Care. 2004;1:219-233
  17. Broderick JP, Conolly S, Feldmann, et al. REPRINT: Guidelines for the Management of Spontaneous Intracerebral Hemorrhage in Adults: 2007 Update: A Guideline From the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation 2007; 116:e391-e413
  18. Adams JG. Emergency Medicine: Clinical Essentials, 2nd ed., Philadelphia, PA:Elsevier-Saunders, 2012;Chapter 103
  19. Edlow J, Selim M. Neurology Emergencies, 1st ed., New York, NY:Oxford University Press, 2010;Chapter 4
  20. Linn J, Bruckmann H (2009) Differential diagnosis of nontraumatic intracerebral hemorrhage. Klin Neuroradiol 19:45-61
  21. Rogers RL, Scalea T, Wallis L, Geduld H. Vascular Emergencies: Expert Management for the Emergency Physician, 1st ed., Cambridge University Press, 2013;Chapter 3
  22. Manji H, Wills A, Kitchen N, Dorwood N, Connolly S, Mehta A. Oxford Handbook of Neurology, 1st ed., Oxford University Press, 2007;Chapter 7
  23. Tintinalli JE, Stapczynski JS, Ma OJ, Yealy DM, Meckler GD, Cline DM. Tintinalli's Emergency Medicine: A Comprehensive Study Guide, 8th ed, McGraw-Hill Education, 2016;Chapter 14
  24. Walls RM, Hockberger RS, Gausche-Hill M. Rosen's Emergency Medicine - Concepts and Clinical Practice, 9th ed, Philadelphia, PA;Elsevier-Saunders, 2018;Chapter 91
  25. Linn J, Bruckmann H (2009) Differential diagnosis of nontraumatic intracerebral hemorrhage. Klin Neuroradiol 19:45–61
  26. American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, and Council on Clinical Cardiology. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage
    A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. May 28, 2015;46(7):2032-2060
  27. Intracerebral Hemorrhage. StatPearls [Internet]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK553103/. [Accessed June 2024]

Contributor(s)

  1. Minckler, Michael, MD
  2. Bouska, River, MD, MPH
  3. Drummond, Brian, MD
  4. Ballarin, Daniel, MD

Updated/Reviewed: June 2024